March 2026 - Pharmaceutical Market Europe

March 2026 - Pharmaceutical Market Europe
Published on 26 March 2026

Description:

Inside this issue: Exploring the UK’s advanced therapy pipeline, closing the hormone gap in women's health, and tackling medicines access delays, plus features on building US media trust for European biotechs and the future of pharma manufacturing.

Preview:

30 articles from this collection:
PME March 2026
PME March 2026
2 Serious People Advert
2 Serious People Advert
3 Comment
3 Comment
4 COMMUNIQUE Awards
4 COMMUNIQUE Awards
Copy of 5 Contents
Copy of 5 Contents
6 News
6 News
Roche and Ascidian agree to $1.8bn neurological disease partnership
7 News
7 News
8 News
8 News
Researchers identify new major cause of inflammatory bowel disease
9 News
9 News
10 NEWS
10 NEWS
11 DERMATOLOGY NEWS
11 DERMATOLOGY NEWS
12 Brian D Smith Darwin’s MEDICINE Corporate mayflies  vs bowhead whales
12 Brian D Smith Darwin’s MEDICINE Corporate mayflies vs bowhead whales
How much time do you spend thinking about the impact of what is working and what is not in today’s organisational reality, versus what was captured in the situational analysis in your brand plan?
13 Mike Dixon WE'RE ALL IN THIS TOGETHER
13 Mike Dixon WE'RE ALL IN THIS TOGETHER
14 MAXINE SMITH AND GARETH HALL LEADING THROUGH OVERWHELM IN PHARMA AND BIOTECH LAUNCHES
14 MAXINE SMITH AND GARETH HALL LEADING THROUGH OVERWHELM IN PHARMA AND BIOTECH LAUNCHES
15 NEIL FLASH - DOES PHARMA HAVE A PROGRESS PROBLEM?
15 NEIL FLASH - DOES PHARMA HAVE A PROGRESS PROBLEM?
16-17 CLINICAL TRIALS AND GENE THERAPY
16-17 CLINICAL TRIALS AND GENE THERAPY
Across almost every sector, brands are multiplying their investment in creativity
18-19 PHARMA MARKET ACCESS
18-19 PHARMA MARKET ACCESS
CAR-Ts pose a unique challenge for healthcare systems, exacerbated by uncertainty around their long-term, real-world value
22-23 WOMEN’S HEALTH
22-23 WOMEN’S HEALTH
24-25 EUROPEAN AND US BIOTECH
24-25 EUROPEAN AND US BIOTECH
26 Lab News Advert
26 Lab News Advert
27 THOUGHT LEADER Anthill
27 THOUGHT LEADER Anthill
28-30 COMMS EXCELLENCE
28-30 COMMS EXCELLENCE
31 THOUGHT LEADER 9 Labs
31 THOUGHT LEADER 9 Labs
Picking your omnichannel direction requires a disciplined, scientific approach
32-33 CANCER GRAND CHALLENGES
32-33 CANCER GRAND CHALLENGES
34-35 PHARMA MANUFACTURING
34-35 PHARMA MANUFACTURING
36 Appointments
36 Appointments
37 Appointments
37 Appointments
38 Appointments
38 Appointments
39 PMPS
39 PMPS
40 Fly Pharma
40 Fly Pharma